Israel’s Glycominds (through its US subsidiary) is to market its multiple sclerosis tests through Multiplan to 20 million subscribers and 900,000 health providers, including hospitals, clinics, laboratories, doctors, and health providers who work with 1,400 insurance companies.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000700322&fid=1725